Compare Novo Nordisk A/S (NVO) vs Nasdaq100 ETF (QQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Nasdaq100 ETF — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while Nasdaq100 ETF trades at $751.27 (market cap $506.92B). The key difference: Nasdaq100 ETF is far larger — about 3.1× Novo Nordisk A/S's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Nasdaq100 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Nasdaq100 ETF for 162 Days on average.
| NVO | QQQ | |
|---|---|---|
Market Cap | $165.31B | $506.92B |
Volume | 11,432,838 | 48,326,518 |
Sector | Health | — |
52-Week High | $63.98 | $759.66 |
52-Week Low | $35.29 | $558.34 |
Typical Hold Time | 116 Days | 162 Days |
Enterprise Value | $179.56B | — |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
QQQ trades at $747.64, down 1.33% on the day, with technical indicators showing a bullish trend supported by moving averages while oscillators remain neutral. The ETF maintains strong institutional interest despite mixed analyst sentiment. Recent news highlights QQQ's concentration in technology stocks and ongoing comparisons with lower-cost alternatives like VOO and QQQM.
The outlook remains positive given QQQ's exposure to leading tech innovators and AI-driven growth potential, though elevated valuations and interest rate sensitivity present near-term risks. Long-term growth prospects appear solid, but investors should monitor concentration risk and fee differentials among competing ETFs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →
